mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy (Q37863123)

24 August 2017

1 reference

title

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy (English)

1 reference

24 August 2017

1 reference

1

Ruth O'Regan

1 reference

24 August 2017

Natalyn Nicole Hawk

2

1 reference

PubMed ID

21476875

24 August 2017

language of work or name

English

0 references

publication date

8 April 2011

1 reference

Expert Opinion on Therapeutic Targets

24 August 2017

1 reference

24 August 2017

15

1 reference

24 August 2017

7

1 reference

24 August 2017

859-872

1 reference

24 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

mTOR regulation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Targeting von Hippel-Lindau pathway in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity i

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Growth hormone excess promotes breast cancer chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575362

10.1517/14728222.2011.575362

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21476875